» Authors » Hugh Rosen

Hugh Rosen

Explore the profile of Hugh Rosen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 129
Citations 6854
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosen H, Roberts E
Adv Pharmacol . 2024 Nov; 101:183-202. PMID: 39521600
Sphingosine-1 phosphate (S1P) modulators have received recent FDA-approval for the treatment of moderate-to-severe ulcerative colitis, including agents ozanimod, approved in 2021, and etrasimod, approved in 2023. These oral drugs are...
2.
Navratilova E, Qu C, Ji G, Neugebauer V, Guerrero M, Rosen H, et al.
Anesthesiology . 2023 Sep; 140(2):272-283. PMID: 37725756
Background: The efficiency of descending pain modulation, commonly assessed with the conditioned pain modulation procedure, is diminished in patients with chronic pain. The authors hypothesized that the efficiency of pain...
3.
Ito H, Navratilova E, Vagnerova B, Watanabe M, Kopruszinski C, Moreira de Souza L, et al.
Brain . 2022 Apr; 146(3):1186-1199. PMID: 35485490
Increased vigilance in settings of potential threats or in states of vulnerability related to pain is important for survival. Pain disrupts sleep and conversely, sleep disruption enhances pain, but the...
4.
5.
Rosen H, Oldstone M
EMBO Mol Med . 2020 Dec; 13(1):e13533. PMID: 33326687
The sphingosine-1-phosphate (S1P) is a lysophospholipid signaling molecule with important functions in many physiological and pathological conditions, including viral infection. In this issue of EMBO Molecular Medicine, Marfia et al...
6.
Huppe C, Blais-Lecours P, Bernatchez E, Lauzon-Joset J, Duchaine C, Rosen H, et al.
Am J Respir Cell Mol Biol . 2020 Apr; 63(2):209-218. PMID: 32289229
In a proportion of patients with hypersensitivity pneumonitis, the biological and environmental factors that sustain inflammation are ill defined, resulting in no effective treatment option. Bioaerosols found in occupational settings...
7.
Page S, Mavrikaki M, Lintz T, Puttick D, Roberts E, Rosen H, et al.
Int J Neuropsychopharmacol . 2019 Oct; 22(11):735-745. PMID: 31613314
Background: New treatments for stress-related disorders including depression, anxiety, and substance use disorder are greatly needed. Kappa opioid receptors are expressed in the central nervous system, including areas implicated in...
8.
Morgan G, Yan N, Mortenson D, Rennella E, Blundon J, Gwin R, et al.
Proc Natl Acad Sci U S A . 2019 Apr; 116(17):8360-8369. PMID: 30971495
In Ig light-chain (LC) amyloidosis (AL), the unique antibody LC protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration....
9.
Guerrero M, Urbano M, Kim E, Gamo A, Riley S, Abgaryan L, et al.
J Med Chem . 2019 Feb; 62(4):1761-1780. PMID: 30707578
κ opioid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stress-related mood disorders including depression, anxiety, and drug abuse, thus the development of novel KOR antagonists...
10.
Baillargeon P, Fernandez-Vega V, Sridharan B, Brown S, Griffin P, Rosen H, et al.
SLAS Discov . 2019 Jan; 24(3):386-397. PMID: 30682260
The Scripps Research Molecular Screening Center (SRMSC) was founded in 2004 and comprises more than $22 million of specialized automation. As part of the Translational Research Institute (TRI), it comprises...